Vanderbilt University Medical Center is launching a first-in-human clinical trial to determine the safety and efficacy of an experimental monoclonal antibody against enterovirus D68 (EV-D68). UNC School of Medicine’s Matthew Vogt, MD, PhD, was a postdoctoral fellow in Pediatric Infectious Diseases at VUMC when he co-led the development of monoclonal antibody therapies against EV-D68.
Read the full story here.